Other News To Note
Friday, June 14, 2013
Cornerstone Therapeutics Inc., of Cary, N.C., said it received on June 11 a Paragraph IV notice letter from Exela Pharma Sciences LLC, of Lenoir, N.C., advising the firm of Exela's filing of a supplemental new drug application for use of an injectable form of nicardipine hydrochloride in 9 percent sodium chloride, a generic version of Cornerstone's Cardene I.V. premixed injection.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.